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Hereditary factors have a strong influence on prostate cancer (PC) risk and poorer outcomes, thus 
stratification by genetic factors addresses a critical need for targeted PC screening and risk-adapted 
follow-up. In this Finnish population-based retrospective study 2283 clinically diagnosed and 455 
screen-detected patients from the Finnish Randomised Study of Screening for Prostate Cancer 
(FinRSPC), 2400 healthy individuals have been involved. Individual genetic risk through establishment 
of a polygenic risk score based on 55 PC risk SNPs identified through the Finnish subset of the 
Collaborative Oncological Gene-Environment Study was assessed. Men with PC had significantly 
higher median polygenic risk score compared to the controls (6.59 vs. 3.83, P < 0.0001). The polygenic 
risk score above the control median was a significant predictor of PC (OR 2.13, 95% CI 1.90–2.39). 
The polygenic risk score predicted the risk of PC with an AUC of 0.618 (95% CI 0.60–0.63). Men in 
the highest polygenic risk score quartile were 2.8—fold (95% CI 2.4–3.30) more likely to develop PC 
compared with men in the lowest quartile. In the FinRSPC cohort, a significantly higher percentage 
of men had a PSA level of ≥ 4 ng/mL in polygenic risk score quartile four compared to quartile one 
(18.7% vs 8.3%, P < 0.00001). Adding the PRS to a PSA-only model contributed additional information 
in predicting pc in the finRSpc model. Results strongly suggest that use of the polygenic risk score 
would facilitate the identification of men at increased risk for PC.
Although prostate cancer (PC) remains the second most common cancer in men, biomarkers for accurate early 
diagnosis are  missing1,2. Owing to the well-known and inherent limitations of using prostate-specific antigen 
(PSA), novel biomarkers to complement PSA for the prediction of PC and particularly PC with unfavourable 
outcomes are  needed3.
Prostate cancer has a very high heritability, with an estimate of 57% (95% CI 0.51–0.63) based on the Nor-
dic Twin Study of  Cancer4, with only a few identified high-risk genes. High penetrance genes, like BRCA1/2, 
HOXB13, CHEK2 and MMR are important, but explain only a fraction of inherited PC  risk5. In addition, the 
nearly 170 single nucleotide polymorphisms (SNPs) associated with PC risk in large genome-wide studies explain 
a quarter of the familial risk, and offer an opportunity to create a polygenic risk score (PRS) to identify the 
subgroups of the population at highest risk of the  disease6,7. Combining a broad array of genetic data into a PRS 
offers an opportunity for accurate prediction of PC  risk8 and allows to highlight the sharp contrast in probability 
of developing the disease between the highest and lowest risk  groups9.
There is evidence of population stratification, i.e. differences between populations in the genetic factors 
contributing to familial PC risk. Previous studies have estimated PRSs mainly based on pooled data from multi-
national cohorts. Instead of using results from mixed European populations, we utilized population-specific PC 
risk loci identified from the Finnish subset from Collaborative Oncological Gene-Environment Study (iCOGS)8.
The aim of our study was to evaluate the potential of PRS to predict PC risk in advance and its application in 
personalized PC diagnosis. Specifically, we evaluated the accuracy of genetic risk stratification to predict overall 
PC, and separately for clinically diagnosed patients and screening trial cases. Moreover, the aim was to assess the 
ability of PRS to predict PC subgroups defined by clinical parameters such as high PSA at diagnosis, aggressive 
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disease and advanced stage. In the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC) 
cohort, we evaluated the additional contribution of PRS to PSA and age.
Results
prostate cancer risk. The median PRS in men with PC was 6.59 (interquartile range (IQR) 8.29) versus 
3.83 (IQR 8.02) among cancer-free controls (p < 0.0001) (Table 1). There was no statistically significant differ-
ence in the median PRS of men with clinically detected (PRS 6.74, IQR 8.41) vs screen-detected (PRS 6.31, IQR 
7.14) cancer.
Of all PC cases, 68.2% had a PRS above the population control’s median (3.83) (Table 2), corresponding to a 
sensitivity of 0.68 (95% CI 0.66–0.70) and specificity of 0.50 (0.48–0.52). The positive predictive value was 0.61 
(95% CI 0.59–0.63) and positive likelihood ratio 1.36 (95% CI 1.30–1.43). Out of men with a clinically diagnosed 
PC, the proportion was 68.7%, while for the screening trial cases 65.9%. The odds ratio for overall PC with a PRS 
above the control median was 2.13 (95% CI 1.90–2.39), the corresponding OR for clinical PC was 2.18 (95% CI 
1.93–2.45) and for screening trial cases was 1.92 (95% CI 1.56–2.37).
When divided into PRS quartiles, PC cases were distributed 18%, 25%, 27% and 30% from the lowest to the 
highest quartile. For the controls, the proportions showed an opposite pattern (33%, 26%, 22%, 19%, respec-
tively). Showing that nearly a third of the PC cases belong to the highest PRS quartile, while one-third of the 
controls belong to the lowest PRS quartile. Men in the highest PRS quartile were of 2.8—fold (95% CI 2.40–3.30) 
higher risk of PC compared with men in the lowest quartile.
The overall receiver operator curve AUC of the PRS to predict PC was 0.618 (95% CI 0.60–0.63, p 4.79E-48), 
for clinically diagnosed PC was 0.622 (95% CI 0.61–0.64, p 4.57E-47), and for screening trial PC cases was 0.597 
(95% CI 0.57–0.63, p 4.42E-11) (Table 2).
prostate cancer clinical parameters. Of the patients with metastatic PC, 75.4% had a PRS above the 
control median, corresponding to an OR of 1.47 (95% CI 1.04–2.06, p 0.028, Table 2) with an AUC of 0.549 (95% 
CI 0.51–0.59). Although, 70.0% of the men with high PSA at diagnosis (PSA > 20 ng/mL) had a PRS above the 
median, no association between the PRS and high PSA at diagnosis could be identified. Similarly, there was no 
significant association between PRS and high Gleason score, advanced stage, tumour and nodal stage or lethal 
PC, possibly due to the nature of the SNPs included and low amount of cases (Table 2).
Table 1.  Polygenic risk score of men predicting prostate cancer in Finland*. *Polygenic risk score is based on 
55 prostate cancer susceptibility loci.
SAMPLE GROUPS N Mean (95% CI) St error of mean Median Variance Standard deviation
Study population 5138 5.99 (5.83–6.16) 0.085 5.01 37.05 6.09
Men without prostate cancer (controls) 
(FinRSPC) 2400 4.71 (4.47–4.94) 0.119 3.83 33.68 5.80
Men with prostate cancer (cases) 2738 7.12 (6.89–7.35) 0.117 6.59 37.28 6.11
Screening trial cases (FinRSPC) 455 6.65 (6.09–7.20) 0.282 6.31 36.22 6.02
Clinical cases (Pirkanmaa Hospital) 2283 7.22 (6.97–7.47) 0.128 6.74 37.45 6.12
Table 2.  Evaluation of polygenic risk score to predict prostate cancer risk and associated clinical measures. 
1 case only investigation; 2versus Gleason score ≤ 6; 3advanced disease stage is defined as T3-4, or N1 or M1; 
OR, odds ratio (polygenic risk score above median was applied as binary variable); AUC, area under the curve 




High PRS N (%) OR (95% CI) P value AUC (95% CI) P value
Risk of prostate cancer:
All prostate cancers (n = 2738) 1868 (68.2) 2.13 (1.90–2.39) 5.92E-39 0.618 (0.60.0.63) 4.79E-48
Clinical prostate cancer cases (n = 2283) 1568 (68.7) 2.18 (1.93–2.45) 1.49E-37 0.622 (0.61–0.64) 4.57E-47
Screening trial prostate cancer cases (n = 455) 300 (65.9) 1.92 (1.56–2.37) 1.11E-9 0.597 (0.57–0.63) 4.42E-11
1Risk of prostate cancer with:
High PSA at diagnosis (> 20 ng/mL) (n = 484) 339 (70.0) 1.12 (0.90–0.39) 0.300 0.517 (0.49–0.54) 0.232
2Aggressive (Gleason score ≥ 8) (n = 368) 235 (63.9) 0.83 (0.65–1.06) 0.140 0.478 (0.44–0.51) 0.206
3Advanced stage (n = 602) 418 (69.4) 1.08 (0.89–1.32) 0.425 0.517 (0.48–0.55) 0.346
Death by prostate cancer (n = 304) 204 (67.1) 0.94 (0.73–1.22) 0.657 0.497 (0.46–0.53) 0.865
Tumour stage (T3-T4) (n = 540) 369 (68.3) 1.01 (0.81–1.25) 0.936 0.512 (0.48–0.54) 0.435
Cancer in nodus (N1 stage) (n = 14) 9 (64.3) 0.84 (0.28–2.51) 0.752 0.443 (0.30–0.58) 0.462
Metastasis (M1 stage) (n = 191) 144 (75.4) 1.47 (1.04–2.06) 0.028 0.549 (0.51–0.59) 0.023
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Further, there was no statistically significant association between the quartiles of the PRS and age at onset of 
PC (χ2 = 3.15; p = 0.369), PSA at diagnosis (χ2 = 3.58; p = 0.311), Gleason score (χ2 = 5.37; p = 0.147) or disease 
stage (χ2 = 1.41; P = 0.703; Supplementary Table 1).
Association with PSA in the subset of FinRSPC cohort: the FinRSPC model. When the FinRSPC 
cohort was divided into negative and positive PSA (PSA < 4 ng/mL vs PSA ≥ 4 ng/mL), the number of men with 
elevated PSA increased in each PRS quartile (Table 3, A). The association between PSA and PRS is illustrated 
by the fact that 8.3% of men in the lowest PRS quartile had PSA ≥ 4 ng/mL compared to 18.7% in the highest 
quartile (χ2 = 32.95; P < 0.00001).
In unadjusted logistic regression within the FinRSPC cohort, both PSA (OR 6.50, 95% CI 5.43–7.80), PRS (OR 
1.06, 95% CI 1.04–1.07) and age (OR 1.04, 95% CI 1.01–1.07) predicted the risk of PC (Table 3, B). After mutual 
adjustment, PRS (OR 1.05, 95% CI 1.00–1.11) was still associated with PC risk, indicating that it contributed 
additional information beyond that provided by PSA.
Discussion
We constructed a population-specific PRS for PC and evaluated its application in genetic risk stratification. The 
Prs was higher among men with PC than the controls, as indicated by the median and proportion above the 
control median, with an odds ratio of 2.13. The AUC was 0.62, with sensitivity of 0.68. The PC risk also increased 
with PRS when it was divided into quartiles. The PRS was associated with metastatic disease, however, it was not 
associated with other indicators of poor prognosis such as high Gleason score or advanced disease. Furthermore, 
within the screening trial, PRS was associated with the proportion of men with positive  PSA10 and contributed 
to detect PC.
Our finding (ROC 0.62) was comparable with previous studies, despite our use of a relatively small number 
of SNPs (n = 55). Previous studies using risk allele based polygenic scores have shown ROC values of 0.54–0.68 
for  PC11–13. However, they have provided only limited evidence that the PRS using common variants improves 
risk  prediction8,12,13.
Genome-wide association studies (GWASs) for metastatic PC are  lacking14 and few studies have investigated 
the association between known germline PC risk variants and metastatic disease diagnosis or development of 
metastasis after initial  treatment14,15. All of the metastatic patients in this cohort had already been found at 
diagnosis due to the retrospective nature of this study. The identified association of PRS with metastatic disease 
at diagnosis is likely due to the inclusion of PC risk SNPs, which have earlier been found to be associated with 
metastatic PC  risk14–16. The lack of association with other clinical variables is in line with earlier findings. Since 
the performance of our PRS was poorer for metastatic disease than PC overall, it offers only limited use for 
individual prediction of the risk of metastasis.
PSA has long been used as the primary biomarker for PC diagnosis, however, PSA screening results 
are frequent in false-positive results and  overdiagnosis17,18. Therefore, population-based screening is not 
 recommended19,20. In this study, we show that in the FinRSPC screening cohort the PRS quartiles are associated 
with elevated PSA of ≥ 4 ng/mL at diagnosis and that the PRS contributed additional information beyond PSA 
and age in predicting PC in the screening trial men. Performance of the PRS in screening needs an additional 
prospective cohort in order to test its applicability for population-based screening to supplement PSA-based 
stewardship in screening for PC.
Table 3.  Evaluation of polygenic risk score in prostate cancer screening in the subset of FinRSPC cohort. 
P value based on χ2 test; PRS, polygenic risk score; PSA, prostate-specific antigen; Q, quartile. OR = odds 
ratio; CI = confidence interval; AUC = area under the receiver operating characteristics curve; PRS, polygenic 
risk score; Predictive performance was assessed using the AUC for individual risk factors and for the genetic 
model including all risk factors. AUC cumulative denotes AUC values obtained when one risk factor at the 
time was added to the model from PSA only to a model including all risk factors. PSA, Age, PRS were used as 
continuous variables. Men aged 55–67 years at the enrollment to the FinRSPC trial.
PRS
PSA < 4 ng/mL PSA ≥ 4 ng/mL % of men with PSA ≥ 4 ng/mL in 
different quartiles (p < 0.00001)N % N %
A) Association between quartile of polygenic risk score and PSA
Q1 (n = 713) 654 27 59 15 8.3%
Q2 (n = 711) 623 25 88 22 12.4%
Q3 (n = 717) 592 24 125 31 17.4%
Q4 (n = 707) 575 24 132 33 18.7%
Risk factor
SIMPLE MODEL MULTIPLE MODEL
OR (95% CI, p) AUC (95% CI, p) OR (95% CI) AUC cumulative (95% CI, p)
B) Simple and multiple logistic regression models including PSA, age, polygenic risk score and their predictive performance to predict prostate cancer
PSA 6.50 (5.43–7.80, 2.61E-90) 0.981 (0.97–0.99, 3.17E-232) 6.60 (5.48–7.95, 8.29E-28) 0.982 (0.97–0.99, 2.70E-232)
Age 1.04 (1.01–1.07, 0.016) 0.557 (0.53–0.59, 0.000116) 1.02 (0.94–1.11, 0.683) 0.557 (0.53–0.59,0.000116)
PRS 1.06 (1.04–1.07, 1.59E-10) 0.597 (0.57–0.63, 4.42E-11) 1.05 (1.00–1.11, 0.038) 0.600 (0.57–0.63, 1.80E-11)
4
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:17075  | https://doi.org/10.1038/s41598-020-74172-z
www.nature.com/scientificreports/
The main strength of the study is that it is population-based, therefore the selection bias is minimized and the 
generalizability is increased. Previous studies have included mainly risk variants (OR > 1) for the construction 
of the  PRS13. We used both risk (per allele OR > 1) and protective (per allele OR < 1) SNPs to capture genetic 
variation in risk more widely. Furthermore, we designed a population-specific risk score, as PC risk variants and 
their frequencies differ between  populations21.
Naturally, the study has some limitations. In the study population there are only few PC deaths and aggres-
sive cases. Since it is based on retrospective data, validation in a prospective setting will elevate the power and 
would potentially improve the study. In particular, application of the PRS in population screening needs to be 
conclusively evaluated in a prospective trial in order to test the PRS for clinical implications and potential benefit. 
Since this a Finnish population based PRS study, application in other, less homogeneous population is needed.
Our findings show that a subgroup of men at an increased risk of PC (OR > 2) can be identified based on 
a PRS. However, the accuracy in predicting was limited (AUC 0.62). The fact that PRS contributed additional 
information above PSA and age suggests that its usefulness in screening is worthwhile.
Materials and methods
All methods were carried out in accordance with relevant guidelines and regulations.
The flow diagram shown in Fig. 1 presents the steps of participant enrolment to the study (A) and selection 
of SNPs for PRS calculation (B).
Study participants. All genotyped PC patients and controls without PC were of Finnish origin. The study 
protocol was reviewed and approved by the research Ethics committee at Pirkanmaa Hospital District (tracking 
numbers R10167, 90,577, R03203). Permission for the use of samples was given by the National Supervisory 
Authority for Welfare and Health (VALVIRA). Informed consent was obtained from the participants involved in 
the study. Altogether, 2738 non-familial PC cases were included in the study. Of them, 2283 were clinical cases 
from the Pirkanmaa Hospital District, and 455 were from the Finnish Randomized Study of Screening for Pros-
tate Cancer (FinRSPC)22, which is the largest component of the European Randomized Study of Screening for 
(a)
(b)
Figure 1.  Flow diagram presenting the steps of participant’s enrollment to the study (a) and selection of SNPs 
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Prostate Cancer (ERSPC)23. Cancer free control subjects (n = 2400) were identified through the FinRSPC  trial22. 
The FinRSPC trial population and the protocol population have been described in detail  elsewhere24. Briefly, 
80,458 men aged 55–67 years were enrolled during 1996–1999, with 32,000 randomised to the screening arm 
and invited to PSA-based screenings at four-year intervals.
Clinical characteristics of the genotyped PC patients, separately for clinically detected and for screening trial 
cases, are summarized in Table 4. PSA at diagnosis was classified as ≤ 20 versus > 20 ng/mL. Gleason score was 
divided into ≤ 6, 7 and ≥ 8. Stage was divided into organ-confined (T1-2, N0/x, M0/x) versus advanced disease 
(T3-4, or N1 or M1). PC death was defined based on the underlying cause recorded as the official cause of death 
by Statistics Finland.
Genotyping and quality control. The original genotyping was carried out by the PRACTICAL (Pros-
tate Cancer Association group to Investigate Cancer Associated Alterations in the Genome) consortium. The 
genotyping outcome was obtained from the use of a custom Illumina Infinium array (iCOGS), as described 
 previously8.
Single nucleotide polymorphism selection and statistical analyses. The Hardy–Weinberg equi-
librium was ensured by checking that the proportion of each genotype obtained was in agreement with the 
expectation calculated from the allele frequencies. Statistical analyses were performed with IBM SPSS version 
25 (SPSS Inc., Chicago, USA) unless otherwise specified. For each SNP, allelic ORs for PC with 95% confidence 
intervals were computed using logistic regression. A total of 55 variants shown to be associated with PC in the 
Finnish subset from iCOGS (Supplementary Table 2) were chosen for the calculation of the PRS based on the 
Table 4.  Baseline clinical characteristics of non-familial prostate cancer patients.
Clinical variables Clinical cases (n = 2283) Screening trial cases (n = 455)
Age at diagnosis
Early onset (≤ 55 y) 103 (4.50) 3 (0.70)
Late onset (> 55 y) 2180 (95.5) 452 (99.3)
Diagnostic PSA level, ng/mL
Low, ≤ 20 1684 (73.8) 415 (91.2)
High, > 20 455 (19.9) 29 (6.40)
Missing data 144 (6.30) 11 (2.40)
Gleason score
Low, ≤ 6 1033 (45.3) 287 (63.1)
High, ≥ 8 329 (14.4) 39 (8.60)
Gleason 7 564 (24.7) 121 (26.6)
Missing data 357 (15.6) 8 (1.80)
T stage
T0/Tx 0 (0.00) 13 (2.90)
T1 746 (32.8) 359 (78.9)
T2 922 (40.3) 50 (11.0)
T3 418 (18.3) 25 (5.50)
T4 96 (4.20) 1 (0.20)
Missing data 101 (4.40) 7 (1.50)
N stage
N0/Nx 2169 (95.0) 447 (98.2)
N1 13 (0.60) 1 (0.20)
Missing data 101 (4.40) 7 (1.50)
M stage
M0/Mx 1999 (87.6) 440 (96.7)
M1 183 (8.00) 8 (1.80)
Missing data 101 (4.40) 7 (1.50)
PSA Progression
Progressed 804 (35.4) 156 (34.3)
Missing data 1479 (64.8) 299 (65.7)
Death
Deceased of PC 296 (13.0) 8 (1.76)
Deceased of else 864 (37.9) 63 (13.9)
Alive 1123 (49.2) 384 (84.4)
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selection criteria described in Fig. 1. In short, selected SNPs were associated with PC at a genome-wide signifi-
cance level (p < 5 × 10–8) and had the effect size of OR > 1.1 for risk SNPs and OR < 0.9 for protective SNPs.
We assessed the PRS of men with and without PC, and also separately for clinically diagnosed and screening 
trial cases. Sensitivity and specificity of the PRS were calculated. The use of the control median as the cut-off-point 
showed a near-optimal sensitivity and specificity. Therefore, the study participants were divided into those with 
a polygenic risk below and above the control median, which represents men free of PC. The odds ratio for PC 
risk prediction relating to the PRS above median was evaluated by logistic regression with PC as the outcome. 
We evaluated the predictive performance of PRS by calculating the area under the curve (AUC) of the receiver 
operator characteristic (ROC). Evaluation of the discriminative potential of the PRS for subsets of cases with 
high PSA at diagnosis, high Gleason score, advanced stage, local and distant progression, and PC death was 
performed with the same methodology.
In order to evaluate the possible implications of the PRS in the screening trial, we evaluated the additional 
contribution of PRS quartiles incremental to PSA and age in predicting PC in the FinRSPC cohort. Logistic 
regression models including PSA, age and the PRS were applied to assess PC prediction and the AUC calculated. 
All reported p values are two-sided.
polygenic risk score calculation. A PRS for each individual was calculated by summing the number of 
risk  alleles25 at each of the 55 SNPs multiplied by the logarithm of the SNP’s OR as follows:
where βi is the per-allele log-odds ratio for locus i, xij represents the number of risk alleles (i.e., 0, 1 or 2) carried 
by an individual j at locus i, and n is the number of loci. The risk conferred by each of the variants is assumed to be 
allele dose-dependent with a multiplicative (log-additive) effect on a relative risk  scale6. Under the multiplicative 
model, the distribution of polygenic risk in the population follows the normal distribution, when relative risk is 
plotted on a logarithmic scale, with mean, μ, and variance σ2. We set the mean, μ = −σ2/2, so that the mean relative 
risk in the population is equal to unity. Log-transformation of non-normally distributed PRS data was applied.
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